Insider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Purchases 3,600 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel acquired 3,600 shares of the stock in a transaction dated Friday, April 25th. The shares were purchased at an average cost of $9.88 per share, with a total value of $35,568.00. Following the completion of the purchase, the chief executive officer now owns 5,570,602 shares of the company's stock, valued at approximately $55,037,547.76. The trade was a 0.06 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Snehal Patel also recently made the following trade(s):

• On Thursday, April 17th, Snehal Patel purchased 5,400 shares of Greenwich LifeSciences stock. The shares were acquired at an average cost of $8.98 per share, with a total value of $48,492.00.
• On Monday, April 7th, Snehal Patel acquired 3,600 shares of Greenwich LifeSciences stock. The stock was acquired at an average price of $9.10 per share, for a total transaction of $32,760.00.
• On Friday, April 4th, Snehal Patel purchased 5,500 shares of Greenwich LifeSciences stock. The stock was acquired at an average cost of $8.73 per share, with a total value of $48,015.00.

Greenwich LifeSciences Trading Up 0.1 %

GLSI traded up $0.01 during trading on Friday, reaching $9.99. The stock had a trading volume of 28,026 shares, compared to its average volume of 45,493. The stock's 50 day moving average is $10.44 and its two-hundred day moving average is $12.11. The company has a market capitalization of $132.61 million, a price-to-earnings ratio of -12.49 and a beta of 1.76. Greenwich LifeSciences, Inc. has a one year low of $8.06 and a one year high of $18.75.

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last announced its earnings results on Tuesday, April 15th. The company reported ($0.61) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.40). On average, equities research analysts predict that Greenwich LifeSciences, Inc. will post -0.8 earnings per share for the current year.

Hedge Funds Weigh In On Greenwich LifeSciences

Hedge funds have recently bought and sold shares of the company. Wells Fargo & Company MN lifted its stake in shares of Greenwich LifeSciences by 54.8% in the fourth quarter. Wells Fargo & Company MN now owns 2,847 shares of the company's stock worth $32,000 after buying an additional 1,008 shares in the last quarter. Brown Brothers Harriman & Co. bought a new position in Greenwich LifeSciences in the 4th quarter valued at approximately $45,000. JPMorgan Chase & Co. boosted its stake in Greenwich LifeSciences by 172.0% during the 4th quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company's stock valued at $79,000 after purchasing an additional 4,465 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Greenwich LifeSciences by 22.3% in the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company's stock worth $82,000 after purchasing an additional 1,322 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in shares of Greenwich LifeSciences by 48.7% during the first quarter. Rhumbline Advisers now owns 9,673 shares of the company's stock valued at $92,000 after buying an additional 3,168 shares during the last quarter. Institutional investors own 4.16% of the company's stock.

Analyst Ratings Changes

Separately, HC Wainwright raised their target price on shares of Greenwich LifeSciences from $38.00 to $39.00 and gave the stock a "buy" rating in a research report on Monday, April 21st.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.